Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea

Accesswire Thursday, 11 July 2019 ()
Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea*SAN FRANCISCO, CA / ACCESSWIRE / July 11, 2019 / *Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc., has agreed in principal to support a U.S.-based University’s request to begin an - Institution Initiated Clinical Research Study. The University will perform a pilot study to evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in non-HIV patients (the “Study”). The Study has received approval from the University’s Institutional Review Board, and Napo Pharmaceuticals, Inc. is currently negotiating the definitive agreement with the University.

Chronic idiopathic diarrhea is a common complaint of patients presenting to family practitioners, internists and is one of the most common reasons for referral to gastroenterologists. It is estimated that the prevalence of chronic idiopathic diarrhea in developed countries (including the U.S.) is approximately 3-5%. It has a significant negative effect on health-related quality of life and causes a high economic burden on patients and society. The American Gastroenterological Association Burden of Illness study (2012) showed that the estimated annual direct and indirect costs associated with chronic idiopathic diarrhea is up to $524 million per year and $136 million per year, respectively.

The planned open-label pilot study will assess the efficacy of crofelemer during a 28-day treatment period in adult, non-HIV patients with chronic idiopathic diarrhea. The study has an expected duration of one year.

*About Crofelemer*

Crofelemer, the active pharmaceutical ingredient being tested, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

*About Jaguar Health, Inc.*

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

*Forward-Looking Statements *

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that University will perform a pilot study to evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in patients. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

*Contact:*

Peter Hodge
Jaguar Health, Inc.
[email protected]
Jaguar-JAGX

*SOURCE:* Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/551597/Jaguar-Healths-Wholly-Owned-Subsidiary-Napo-Pharmaceuticals-Inc-Commits-to-Support-Study-Evaluating-the-Effect-of-Crofelemer-on-Patients-With-Chronic-Idiopathic-Diarrhea
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million

Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million
*Maturity Date of Remaining Merger-related Debt is December 31, 2020* *SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 /* Jaguar Health, Inc. (NASDAQ: JAGX)...
Accesswire

Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering

Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering
*SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2019 / *Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical...
Accesswire

PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499

HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to...
GlobeNewswire

Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer...
GlobeNewswire


Other recent news in Press Releases

Apollo Endosurgery, Inc. to Report SECOND QUARTER Results on July 23, 2019SOFTWARE AG Partners with Microsoft to Accelerate, Simplify Cloud Migrations
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.